Spontaneous Single-Duct Bloody Nipple Discharge With Negative Imaging
A 47-year-old woman has had 3 weeks of spontaneous, bloody discharge from a single duct of the right breast. She can express it with one finger and has stained two bras. There is no palpable mass and no skin or nipple change, and she takes no hormonal medication. Bilateral digital breast tomosynthesis with diagnostic views and targeted retroareolar ultrasound are negative: no mass, no suspicious calcification, and the ducts are not dilated. The study is assigned BI-RADS 1 and the referring clinician asks you what to do next. The patient has read that MRI "finds what mammograms miss" and requests it, and she is reluctant to consider surgery for what she considers a cosmetic problem.
1. What is the next step, and how do you justify it over contrast-enhanced MRI?
Read the worked answer
The key discriminator is that this is true pathologic discharge: spontaneous, single duct, and frankly bloody. That pattern carries a meaningful malignancy rate (roughly 5–15%, mostly DCIS or papillary carcinoma), with intraductal papilloma the most common benign cause. Bilateral, multiduct, expressed-only, green or milky discharge does not carry that risk.
Negative mammography and ultrasound do not exclude an intraductal lesion, so the next step is referral for duct excision (microdochectomy) with pathologic correlation, with or without preoperative localization. Ductography can demonstrate a filling defect and map the involved duct for the surgeon, but it is technically demanding, frequently fails, and does not change the decision to excise.
Contrast-enhanced MRI has high sensitivity but limited specificity in the retroareolar region, and small papillomas and DCIS can be MRI-occult. A negative MRI therefore cannot be used to defer excision. MRI is reasonable for surgical planning or if the patient refuses surgery, but she must be told that a negative study does not mean benign.
2. She refuses surgery outright. Construct a defensible management plan and state what you will document.
Read the worked answer
This is informed refusal of the guideline-concordant step, so the plan must be explicit, shared, and documented rather than quietly replaced by imaging.
- Document the residual risk in her words: a single-duct bloody discharge has a roughly 5–15% chance of underlying malignancy that imaging has not excluded, and no imaging test closes that gap.
- Offer MRI as risk-reduction, not exclusion - it may find a clinically occult lesion or guide a later operation, but a negative result leaves residual risk and does not substitute for tissue.
- Offer a defined observation window (clinical breast exam plus imaging at 3–6 months) with explicit return precautions: any mass, skin change, increase in discharge, or new pain prompts immediate reassessment and re-referral to breast surgery.
- Arrange a surgical second opinion rather than abandoning the referral.
- Do not send nipple discharge for cytology - sensitivity is too low to be reassuring.
State in the note that observation is a patient-preference deviation from standard care, that risks and alternatives were discussed, and that she may re-engage at any time without prejudice.
3. How would your recommendation change if the discharge were bilateral, expressible from multiple ducts, and greenish, with the same negative imaging?
Read the worked answer
It would change completely, and this is the reasoning the case is testing.
Multiduct, bilateral, greenish or milky discharge produced mainly on expression is physiologic or due to duct ectasia / periductal mastitis, not a sign of occult carcinoma. The pretest probability of malignancy is low enough that the negative mammogram and ultrasound are genuinely reassuring.
The management is reassurance, supportive care, and smoking cessation where relevant, with no duct excision, no ductography, and no MRI. Antibiotics are worth considering only if there are signs of periductal inflammation; recurrent symptoms may eventually warrant surgical referral for duct ectasia, but that is a quality-of-life decision, not an oncologic one.
The contrast between the two scenarios - same negative imaging, opposite recommendation - turns on three features: spontaneity, single versus multiple ducts, and bloody versus non-bloody. Those features, not the imaging, drive the decision.